On the stock market since 2017, it operates in the world of health and science. It has 705 employees. Now — the numbers.
This is an established company with proven profits.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Average growth of 97% a year over the last 4 years. Red columns mark years that ended in a loss.
The two sides balance each other out — the picture is neither a safety net nor an alarm.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
An investor who bought at the very peak is down 80% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 3 years, sales grew about 137% a year on average.
The average analyst price target is $32.50 — 72% above today’s price.
The company’s market value is 108 times its annual profit. Even a small disappointment could hit the price hard.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 0/10.
On our five-subject report card, APLS sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: APLS is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.